BioDlink Sets March Board Meeting to Approve 2025 Annual Results

TOT BIOPHARM International Co. Ltd. ( (HK:1875) ) has shared an update.

BioDlink International Company Limited has scheduled a board meeting for 18 March 2026 to review and approve the group’s annual results for the financial year ended 31 December 2025. The meeting may also address other corporate matters, signaling an upcoming disclosure of the company’s financial performance that will be closely watched by investors for insights into operational health and future direction.

The board currently consists of executive director Mr. Fu Shan, non-executive director Dr. Liu Weidong and independent non-executive directors Ms. Sun Hui, Mr. Zhang Qing and Dr. Gu Xuelin, underscoring the company’s adherence to Hong Kong corporate governance norms. Confirmation of this board structure alongside the results timetable helps provide transparency to shareholders and the market ahead of the annual earnings announcement.

The most recent analyst rating on (HK:1875) stock is a Hold with a HK$4.50 price target. To see the full list of analyst forecasts on TOT BIOPHARM International Co. Ltd. stock, see the HK:1875 Stock Forecast page.

More about TOT BIOPHARM International Co. Ltd.

BioDlink International Company Limited, listed on the Hong Kong Stock Exchange under stock code 1875, operates through a group structure that includes various subsidiaries. The company is governed by a board comprising an executive director, a non-executive director and several independent non-executive directors, reflecting a standard Hong Kong listed-company governance setup.

Average Trading Volume: 3,731,713

Technical Sentiment Signal: Buy

Current Market Cap: HK$3.1B

Find detailed analytics on 1875 stock on TipRanks’ Stock Analysis page.